# Efficacy of Semaglutide in Glycemic Control, Weight Loss, and Improving Lipidogram- Role of Baseline Vitamin D Levels

> **NCT07043361** · — · COMPLETED · sponsor: **Hillel Yaffe Medical Center** · enrollment: 5300 (actual)

## Conditions studied

- Metabolic Disease

## Interventions

- **DRUG:** semaglutide

## Key facts

- **NCT ID:** NCT07043361
- **Lead sponsor:** Hillel Yaffe Medical Center
- **Sponsor class:** OTHER_GOV
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2023-12-18
- **Primary completion:** 2024-12-21
- **Final completion:** 2025-04-30
- **Target enrollment:** 5300 (ACTUAL)
- **Last updated:** 2025-07-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07043361

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07043361, "Efficacy of Semaglutide in Glycemic Control, Weight Loss, and Improving Lipidogram- Role of Baseline Vitamin D Levels". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT07043361. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*